°æµµÀÎÁöÀå¾Ö ½ÃÀå : ÀûÀÀÁõº°, Áúȯ À¯Çüº°, ¿¬·É´ëº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Mild Cognitive Impairment Market, By Indication, By Disease Type, By Age Group, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå
:
1536677
¸®¼Ä¡»ç
:
AnalystView Market Insights
¹ßÇàÀÏ
:
2024³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 311 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
º¸°í¼ ÇÏÀ̶óÀÌÆ®
°æµµÀÎÁöÀå¾Ö ½ÃÀå ±Ô¸ð´Â 2023³â 19¾ï 8,021¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 5.24% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°æµµÀÎÁöÀå¾Ö ½ÃÀå - ½ÃÀå ¿ªÇÐ
³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í Áø´Ü ¹æ¹ýÀÇ ¹ßÀüÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»ó
MCI ¹× ±âŸ ÀÎÁö Àå¾ÖÀÇ À¯º´·üÀº Àα¸ Áõ°¡¿Í ÇÔ²² Áõ°¡ÇÕ´Ï´Ù. °í·É Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ Áø´Ü µµ±¸, Ä¡·á ¹× °ü¸® Àü·«¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°øÀÚ¿Í ÀϹÝÀÎ »çÀÌ¿¡¼ MCI¿¡ ´ëÇÑ Àνİú ÀÌÇØ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áø´Ü ¹æ¹ýÀÇ ¹ßÀü°ú ±³À°Àû ³ë·ÂÀÇ Áõ°¡´Â ¹ß°ßÀ²ÀÇ Çâ»ó°ú ÈÄ¼Ó °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ÀÎÁö °Ç° ¹× °ü·Ã ºÐ¾ß¿¡ ´ëÇÑ ÀÇ·áºñ ÁöÃâ Áõ°¡´Â MCI °ü·Ã Á¦Ç° ¹× ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ¹Î°£ ºÎ¹®Àº ÀÎÁö Àå¾Ö¿¡ ´ëÇÑ ´õ ³ªÀº Ä¡·á ¼Ö·ç¼Ç¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÎÁö ÈÆ·Ã ¾Û, ¿ø°ÝÀÇ·á, ¿þ¾î·¯ºí ±â±â µî µðÁöÅÐ °Ç° ±â¼úÀÇ ºÎ»óÀ¸·Î MCI °ü¸® ¹× ¸ð´ÏÅ͸µÀÌ °ÈµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀº ȯÀÚ Âü¿©µµ¸¦ ³ôÀ̰í Ä¡·á¿Í ¿¬±¸¿¡ »õ·Î¿î ±æÀ» ¿¾îÁÖ¸ç, MCI Áõ»ó °ü¸®¿Í ÁøÇà ¾ïÁ¦¸¦ À§ÇÑ ¾à¹°ÀÇ °³¹ßÀº ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀÔ´Ï´Ù. »õ·Î¿î Ä¡·áÁ¦¿Í ÀÓ»ó½ÃÇèÀº Á¦¾à ºÐ¾ßÀÇ ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù.
°æµµÀÎÁöÀå¾Ö ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®
´ç»çÀÇ ¸®¼Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 524%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀûÀÀÁõ ¼¼ºÐȸ¦ ±âÁØÀ¸·Î ¾ËÃ÷ÇÏÀ̸Ӻ´(AD) ºÎ¹®Àº ¾ËÃ÷ÇÏÀ̸Ӻ´ À¯º´·ü Áõ°¡·Î ÀÎÇØ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.
Áúº´ À¯Çüº°·Î´Â ³ë³âÃþÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ 2023³â Áúº´ À¯Çüº°·Î´Â ¹«Áõ»óÇüÀÌ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.
¿¬·É´ëº°·Î´Â ¾ËÃ÷ÇÏÀ̸Ӻ´, Ç÷°ü¼º Ä¡¸Å µî Ä¡·á ¼ö¿ä°¡ ³ôÀº ³ë³âÃþÀÌ 2023³â ÁÖ¿ä ¿¬·ÉÃþÀ¸·Î ºÎ»óÇß½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ³ôÀº ¹ßº´·ü·Î ÀÎÇØ ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.
°æµµÀÎÁöÀå¾Ö ½ÃÀå - ¼¼ºÐÈ ºÐ¼®:
°æµµÀÎÁöÀå¾Ö ¼¼°è ½ÃÀåÀº ÀûÀÀÁõ, Áúº´ À¯Çü, ¿¬·É´ë ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐȵ˴ϴÙ.
ÀûÀÀÁõ¿¡ µû¶ó ½ÃÀåÀº ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å, Ç÷°ü¼º Ä¡¸Å, ·¹ºñ¼ÒüÇü Ä¡¸Å, ÆÄŲ½¼º´ Ä¡¸Å, ±âŸ µî 5°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. Ä¡¸Å Ä¡·á¿¡´Â °æ¹ÌÇÑ ÀÎÁö ±â´É Àå¾Ö°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀåÀº Áúȯ À¯Çü¿¡ µû¶ó °Ç¸ÁÁõ¼º MCI¿Í ºñ°Ç¸ÁÁõ¼º MCI·Î ³ª´¹´Ï´Ù. ±¹³» MCI ½ÃÀåÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ç¸ÁÁõ¼º °æµµÀÎÁöÀå¾Ö´Â ±â¾ï·Â °á¼ÕÀ» ³ªÅ¸³»¸ç, ½É°¢ÇÑ »óÅ´ ¾Æ´ÏÁö¸¸ ³ëÀÎµé »çÀÌ¿¡¼ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
½ÃÀåÀº ¿¬·É´ëº°·Î ¼Ò¾Æ, ¼ºÀÎ, ³ë³âÃþÀ¸·Î ³ª´¹´Ï´Ù. ³ë³âÃþÀÌ ½ÃÀåÀ» Áö¹èÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ °É¸®°Å³ª °æ¹ÌÇÑ ÀÎÁö Àå¾Ö¸¦ ¾Î°í ÀÖ´Â ³ëÀεéÀÌ ÀÌ ºÎ¹®ÀÇ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
°æµµÀÎÁöÀå¾Ö ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®
Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ºÏ¹Ì°¡ °æµµÀÎÁöÀå¾Ö ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ³ëÀÎ Àα¸°¡ ¸¹°í Áõ°¡ Ãß¼¼¿¡ Àֱ⠶§¹®¿¡ MCI À¯º´·üÀÌ ³ô½À´Ï´Ù. Á¶±â Áø´Ü°ú Ä¡·á¸¦ Áö¿øÇϴ ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿Í ÇÔ²² ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚµµ Ȱ¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾Æ¿¡¼ ÀϺ»Àº °í·ÉÀÚ ºñÀ²ÀÌ ³ô°í ÀÎÁöÀå¾Ö °ü·Ã ¿¬±¸°³¹ßÀÇ ¼±µÎÁÖÀÚÀÔ´Ï´Ù. ÀϺ»¿¡¼´Â MCI¸¦ °ü¸®Çϱâ À§ÇÑ ÀÇ·á ¼ºñ½º°¡ Àß °®Ãß¾îÁ® ÀÖ½À´Ï´Ù.
°æµµÀÎÁöÀå¾Ö ½ÃÀå - °æÀï »óȲ:
°æÁõÀÎÁöÀå¾Ö ½ÃÀåÀº °æÀïÀÌ Ä¡¿ÇÕ´Ï´Ù. ½ÃÀå¿¡ ÁøÀÔÇÑ ±â¾÷µéÀº MCI ¹× °ü·Ã ÀÎÁö Àå¾Ö¸¦ °ü¸®Çϱâ À§ÇÑ ¾à¹° ¹× Ä¡·á¹ý °³¹ß¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÁ¨°ú À϶óÀÌ ¸±¸®¿Í °°Àº ±â¾÷µéÀº ¾ËÃ÷ÇÏÀ̸Ӻ´°ú MCI¿Í Áߺ¹µÉ ¼ö ÀÖ´Â ´Ù¸¥ ½Å°æ ÅðÇ༺ Áúȯ¿¡ ´ëÇÑ Ä¡·áÁ¦¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. °·ÂÇÑ R&D ÆÄÀÌÇÁ¶óÀÎÀ» º¸À¯ÇÑ ±â¾÷Àº Ä¡·á¿Í Áø´ÜÀ» ¹ßÀü½ÃŰ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿¿Í ÀǾàǰ °³¹ßÀÇ Çõ½ÅÀº Áß¿äÇÑ °æÀï ¿ä¼Ò·Î ÀÛ¿ëÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå °³¿ä
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå °æµµÀÎÁöÀå¾ÖÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
½ÃÀå Àü¸Á µ¿Çâ
Á¦4Àå °æµµÀÎÁöÀå¾Ö »ê¾÷ ¿¬±¸
PEST ºÐ¼®
Porter's Five Forces ºÐ¼®
¼ºÀå Àü¸Á ¸ÅÇÎ
±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ºÐ¼®
Á¦5Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®
COVID-19 ÀÌÀüÀÇ ¿µÇ⠺м®
COVID-19 ÀÌÈÄÀÇ ¿µÇ⠺м®
Á¦6Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå »óȲ
°æµµÀÎÁöÀå¾Ö ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
ÁÖ¿ä Á¦Á¶¾÷üº° ³»¿ª µ¥ÀÌÅÍ
±âÁ¸ ±â¾÷ ºÐ¼®
½ÅÈï ±â¾÷ ºÐ¼®
Á¦7Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå - ÀûÀÀÁõº°
°³¿ä
ºÎ¹® Á¡À¯À² ºÐ¼®(ÀûÀÀÁõº°)
¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡¸Å
Ç÷°ü¼º Ä¡¸Å
·çÀ̼Òü Ä¡¸Å
ÆÄŲ½¼º´ Ä¡¸Å
±âŸ
Á¦8Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå - Áúȯ À¯Çüº°
°³¿ä
Áúº´ À¯Çüº° ºÎ¹® Á¡À¯À² ºÐ¼®
°Ç¸Á¼º MCI
ºñ°Ç¸Á¼º MCI
Á¦9Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå - ¿¬·ÉÃþº°
°³¿ä
¿¬·ÉÃþº° ºÎ¹® Á¡À¯À² ºÐ¼®
¾Æµ¿
¼ºÀÎ
°í·ÉÀÚ
Á¦10Àå °æµµÀÎÁöÀå¾Ö ½ÃÀå - Áö¿ªº°
¼Ò°³
ºÏ¹Ì
°³¿ä
ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
¹Ì±¹
ij³ª´Ù
À¯·´
°³¿ä
À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
¿µ±¹
ÇÁ¶û½º
·¯½Ã¾Æ
³×´ú¶õµå
½º¿þµ§
Æú¶õµå
±âŸ
¾Æ½Ã¾ÆÅÂÆò¾ç(APAC)
°³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
Àεµ
Áß±¹
ÀϺ»
Çѱ¹
È£ÁÖ
ű¹
Àεµ³×½Ã¾Æ
Çʸ®ÇÉ
±âŸ
¶óƾ¾Æ¸Þ¸®Ä«
°³¿ä
¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
±âŸ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°³¿ä
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
ÅÍŰ
¾ËÁ¦¸®
ÀÌÁýÆ®
±âŸ
Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - °æµµÀÎÁöÀå¾Ö ¾÷°è
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä
Eli Lilly and Company
Biogen Inc.
Roche Holding AG
Axovant Gene Therapies Ltd.
GE Healthcare
Philips Healthcare
Neurotrack Technologies
Cogstate Ltd.
Lumosity Inc.
Alzheimer's Drug Discovery Foundation(ADDF)
AstraZeneca
Novartis International AG
Takeda Pharmaceutical Company Limited
Denali Therapeutics Inc.
HappyNeuron
Others
Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á
ksm
¿µ¹® ¸ñÂ÷
REPORT HIGHLIGHT
Mild Cognitive Impairment Market size was valued at USD 1,980.21 Million in 2023, expanding at a CAGR of 5.24% from 2024 to 2032.
Mild Cognitive Impairment (MCI) is a kind of disease characterized by noticeable changes in cognitive function that are greater than expected for a person's age but not severe enough to interfere significantly with daily life. People with MCI might experience difficulties with memory, language, thinking, or judgment that are noticeable to themselves or others.
Mild Cognitive Impairment Market- Market Dynamics
The growing older population and advancement in diagnostic methods are expected to propel market demand
The prevalence of MCI and other cognitive disorders increases as the population rises. The growing number of older fuels demand diagnostic tools, treatments, and management strategies. There is a greater awareness and understanding of MCI among healthcare providers and the public. Advances in diagnostic methods and increased educational efforts contribute to higher detection rates and subsequent demand for interventions.
Further, increased healthcare spending on cognitive health and related areas drives demand for MCI-related products and services. Governments and private sectors are investing in better care solutions for cognitive disorders. The rise of digital health technologies, such as cognitive training apps, telemedicine, and wearable devices, enhances the management and monitoring of MCI. Technology improves patient engagement and provides new avenues for treatment and research. The development of drugs aimed at managing symptoms or modifying the progression of MCI influences market dynamics. New therapeutic agents and clinical trials contribute to growth in the pharmaceutical sector.
Mild Cognitive Impairment Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 524% over the forecast period (2024-2032)
Based on Indication segmentation, the Alzheimer's disease (AD) segment was predicted to show maximum market share in the year 2023, owing to the increased prevalence of Alzheimer's disease.
Based on Disease Type segmentation, the amnestic segment was the leading Disease Type in 2023, due to high prevalence among older adults.
Based on Age Group segmentation, the geriatric segment was the leading Age Group in 2023, owing to the high need for treatment of Alzheimer's, vascular dementia, etc.
On the basis of region, North America was the leading revenue generator in 2023, mainly due to the high incidence of Alzheimer's disease.
Mild Cognitive Impairment Market- Segmentation Analysis:
The Global Mild Cognitive Impairment Market is segmented on the basis of Indication, Disease Type, Age Group, and Region.
The market is divided into five categories based on Indication: Alzheimer's Disease, Vascular Dementia, Lewy Body Dementia, Parkinson's Disease Dementia, and others. The Alzheimer's Disease Dementia segment dominates the market. Mild cognitive impairment is needed for dementia cure which is contributing to segment growth.
The market is divided into two categories based on Disease Type: amnestic MCI and non-amnestic MCI. The amnestic MCI segment is projected to hold the largest share of the market. Amnestic mild cognitive impairment indicates memory deficiency and is not so severe condition but is growing among old age people.
The market is divided into three categories based on Age Group: child, adult, and geriatric. The geriatric segment dominates the market and is expected to maintain its high dominance during the forecast period. Older age people suffering from Alzheimer's and having mild cognitive impairment issue are boosting segment demand.
Mild Cognitive Impairment Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the Mild Cognitive Impairment market. The U.S. has a large and growing elderly population, contributing to a high prevalence of MCI. There is significant investment in research and development, along with advanced healthcare infrastructure that supports early diagnosis and treatment. In Asia, Japan has a high proportion of elderly individuals and is a leader in research and development related to cognitive impairments. The country has well-established healthcare services for managing MCI.
Mild Cognitive Impairment Market- Competitive Landscape:
The Mild Cognitive Impairment market is moderately competitive. The companies in the market are involved in developing drugs and therapies aimed at managing MCI and related cognitive disorders. Companies like Biogen and Eli Lily are developing treatments for Alzheimer's disease and other neurodegenerative conditions that can overlap with MCI. Companies with strong research and development pipelines are crucial in advancing treatments and diagnostics. Innovation in biomarkers and drug development are key competitive factors.
Recent Developments:
In July 2022, La Roche received FDA approval for the Elecsys Amyloid Plasma panel in the treatment of Alzheimer's disease.
In 2022, Teva Pharmaceuticals launched a generic Revlimid capsule for mild cognitive impairment care.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MILD COGNITIVE IMPAIRMENT MARKET KEY PLAYERS
Eli Lilly and Company
Biogen Inc.
Roche Holding AG
Axovant Gene Therapies Ltd.
GE Healthcare
Philips Healthcare
Neurotrack Technologies
Cogstate Ltd.
Lumosity Inc.
Alzheimer's Drug Discovery Foundation (ADDF)
AstraZeneca
Novartis International AG
Takeda Pharmaceutical Company Limited
Denali Therapeutics Inc.
HappyNeuron
Others
GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032
Alzheimer's Disease
Vascular Dementia
Lewy Body Dementia
Parkinson Disease Dementia
Others
GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032
Amnestic MCI
Non-amnestic MCI
GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019-2032
GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
1. Mild Cognitive Impairment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Mild Cognitive Impairment Market Snippet by Indication
2.1.2. Mild Cognitive Impairment Market Snippet by Disease Type
2.1.3. Mild Cognitive Impairment Market Snippet by Age Group
2.1.4. Mild Cognitive Impairment Market Snippet by Country
2.1.5. Mild Cognitive Impairment Market Snippet by Region
2.2. Competitive Insights
3. Mild Cognitive Impairment Key Market Trends
3.1. Mild Cognitive Impairment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Mild Cognitive Impairment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Mild Cognitive Impairment Market Opportunities
3.4. Mild Cognitive Impairment Market Future Trends
4. Mild Cognitive Impairment Industry Study
4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Mild Cognitive Impairment Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Mild Cognitive Impairment Market Landscape
6.1. Mild Cognitive Impairment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players' Analysis
6.2.2. Emerging Players' Analysis
7. Mild Cognitive Impairment Market - By Indication
7.1. Overview
7.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
7.1.2. Alzheimer's Disease Dementia
7.1.3. Vascular Dementia
7.1.4. Lewy Body Dementia
7.1.5. Parkinson Disease Dementia
7.1.6. Others
8. Mild Cognitive Impairment Market - By Disease Type
8.1. Overview
8.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
8.1.2. Amnestic MCI
8.1.3. Non-amnestic MCI
9. Mild Cognitive Impairment Market - By Age Group
9.1. Overview
9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
9.1.2. Child
9.1.3. Adult
9.1.4. Geriatric
10. Mild Cognitive Impairment Market- By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Mild Cognitive Impairment Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Mild Cognitive Impairment Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Mild Cognitive Impairment Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Mild Cognitive Impairment Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Mild Cognitive Impairment Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Mild Cognitive Impairment Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Eli Lilly and Company
11.2.2. Biogen Inc.
11.2.3. Roche Holding AG
11.2.4. Axovant Gene Therapies Ltd.
11.2.5. GE Healthcare
11.2.6. Philips Healthcare
11.2.7. Neurotrack Technologies
11.2.8. Cogstate Ltd.
11.2.9. Lumosity Inc.
11.2.10. Alzheimer's Drug Discovery Foundation (ADDF)
11.2.11. AstraZeneca
11.2.12. Novartis International AG
11.2.13. Takeda Pharmaceutical Company Limited
11.2.14. Denali Therapeutics Inc.
11.2.15. HappyNeuron
11.2.16. Others
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
°ü·ÃÀÚ·á